Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by princeofcuton Jul 08, 2015 3:46pm
68 Views
Post# 23904455

RE:RE:RE:RE:RE:RE:Great News plus low volume equals continued drop in price

RE:RE:RE:RE:RE:RE:Great News plus low volume equals continued drop in priceGV, ROTFLMAO...i am well trained and practiced in the art of writing to the crowd and this (investment MB's) is comedy central most days..and when i post that pikupstix, etc. entertain me and i deserve i mean it  (his pretenious self-aggrandizing self-importance is denuded by the fact he writes copy for a baby biotech, that is just so funny)  ...and i write to the way others post, you i perceive a gentlemen so i write to you respectfully others well they provide me entertainment...ps i actually write business reports regularly, with the purpose to persuade and am quite successful at it, last report was about 120 pages (about average for what i write), was an industry/goverment advocacy piece and likely quite influential (well written, well researched, authoritative, etc., or so i was told by the government officials)...this MB is like comics found in bubblegum wrappers...ps risks i write about re. chinee, etc. are real based on experience...also no PIII from FDA is a huge sell signal as IMO FDA will not accept other country trial data exclusively for registration trials and US is likely 2 times bigger (revenue, profit, etc.) than ROW.  i believe registration trials must be FDA approved and RVX should know this  ( i suspect RVX will be required to make significant changes and additions to plan, IMO adding lipitor is one such buckle under, i also see a 208 arm by itself) regards
Bullboard Posts